Overall, current data support a context-dependent role for persistent senescence in treatment resistance, but do not establish TIS as a universal or independent cause of therapeutic failure.
Abstract
Simple Summary Cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and, in selected settings, immunotherapy can induce cellular senescence, a state characterized by durable cell-cycle withdrawal. Senescence may initially contribute to tumor control, but persistent senescent cells can also modify the tumor microenvironment, alter inflammatory signaling, and support tumor-cell plasticity or survival. Importantly, senescent cells may be present before treatment as a consequence of aging, chronic inflammation, environmental stress, fibrosis, or oncogenic signaling. This review therefore considers therapy-induced senescence (TIS) within its broader tissue context and examines evidence linking senescence-associated phenotypes to treatment response, resistance, and recurrence. We distinguish mechanistic and preclinical evidence from clinical associations and from clinically validated findings, and we discuss the limitations of current senescence biomarkers. Finally, we evaluate senolytic, senomorphic, and sequential “one–two punch” strategies, emphasizing that most therapeutic evidence remains preclinical and that biomarker-guided treatment timing and patient selection remain unresolved.
The biological mechanisms regulating cellular senescence are summarized, its contrasting roles in cancer development are highlighted, emerging therapeutic approaches are discussed, and current challenges and future directions for translating senescence-based therapies into clinical oncology are outlined.
Awateef Fatima, Saba Yousuf· International Journal of Inn...· 0 citations
Therapy-induced senescence (TIS) has emerged as a central biological response to anticancer therapies, extending beyond tumor suppression to influence long-term tissue homeostasis, cardiovascular (CV) remodeling, and accelerated biological aging. In breast cancer (BC), chemotherapy, radiotherapy, targeted therapies, an...
Eugenia Belcastro, G. Fanelli, Maria Luisa Schiavone et al.· Frontiers in Cardiovascular...· 0 citations
Therapy-induced sCAF offers a plausible framework for understanding post-CCRT microenvironmental remodeling and treatment resistance in cervical cancer, and the mechanisms by which they may contribute to treatment resistance are evaluated.
Jing-Yang Lan, Cheng-Ming Tian, Tong Wang et al.· BMC Medicine· 0 citations
This mechanistic view shifts the therapeutic question from how broadly to activate T cells to which states should be generated, preserved, or rescued and provides a testable basis for state-informed biomarker development and therapeutic design.
Jia-Shu Han, Xiaohong Lyu, Meng-Wei Wu et al.· Cancer Letters· 0 citations
A simple clearance to resistance framework is proposed that links acute protective stress responses, chronic tumor-promoting adaptation, and naturally evolved cancer resistance, and naturally evolved cancer resistance by cancer resistant subterranean mammals.
Yan-Dong Xu, Yang Zhao· Ageing and Cancer Research &...· 0 citations
This review summarizes current evidence suggesting that senescent cells persistence is attributable not only to immune system decline but also to active, cell-intrinsic mechanisms of immune evasion and highlights emerging therapeutic strategies aimed at targeting the immune evasion of senescent cells.
Qikun Ou, Jin-Ran Zhao, Yuanlong Ge et al.· Ageing and Cancer Research &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.